ERBB2-Mutated Metastatic Lung Adenocarcinoma With Leptomeningeal Progression

This lung cancer diagnosis at a glance

Subtype
Adenocarcinoma
Biomarkers
ERBB2 A775_G776 insYVMA mutation with amplification
Sex
male
Spread to
leptomeninges
Treatment
chemotherapy, targeted therapy and immunotherapy
Outcome
Setback / Progression

Treatment course, step by step

  1. He received carboplatin and pemetrexed.
  2. Pemetrexed maintenance followed, with a partial response during 6 months of treatment.
  3. Afatinib was given for 1.5 months before progression.
  4. Nivolumab was given for 2 months before progression.
  5. Trastuzumab plus docetaxel was given for 3 months and produced a mixed systemic response, but leptomeningeal disease developed.

What happened, in summary

A man with metastatic lung adenocarcinoma had an ERBB2 A775_G776 insYVMA mutation together with ERBB2 amplification. He had never smoked. Carboplatin and pemetrexed followed by pemetrexed maintenance produced a partial response over 6 months. The cancer then progressed during 1.5 months of afatinib treatment. Nivolumab was given for 2 months, but the disease continued to progress. He next received trastuzumab plus docetaxel for 3 months. This produced a mixed response in the systemic disease, while leptomeningeal disease developed. His cancer therefore progressed despite several chemotherapy, HER2-directed and immunotherapy approaches.

Where this story comes from

This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full

How we source and attribute stories Accuracy and limitations

Collections this story belongs to

Similar lung cancer stories

These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer

Search more lung cancer stories